Enanta Pharmaceuticals (ENTA) Free Cash Flow (2012 - 2026)

Enanta Pharmaceuticals has reported Free Cash Flow for 15 years, with the latest figure at -$7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 55.25% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at -$9.6 million (up 88.32% YoY), and the FY2025 full-year result was -$32.2 million, up 66.74% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$7.2 million, up from -$11.8 million in the prior quarter.
• The five-year high for Free Cash Flow was $27.4 million in Q2 2025, with the low at -$38.8 million in Q4 2022.
• Historically, Free Cash Flow has averaged -$19.6 million across 5 years, with a median of -$21.9 million in 2024.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 468.4% — and 2025, when it jumped 246.21%.
• Enanta Pharmaceuticals' Free Cash Flow stood at -$38.8 million in 2022, then soared by 33.56% to -$25.8 million in 2023, then increased by 0.89% to -$25.5 million in 2024, then surged by 53.64% to -$11.8 million in 2025, then soared by 39.44% to -$7.2 million in 2026.
• The last three Free Cash Flow figures came in at -$7.2 million (Q1 2026), -$11.8 million (Q4 2025), and -$18.0 million (Q3 2025), per Business Quant data.